CAJ | 학술논문

目的：评价利奈唑胺治疗神经外科术后颅内感染的临床疗效及安全性，为术后颅内感染的治疗提供参考。方法通过病历查询系统收集2011年1月-2012年12月北京天坛医院51例术后颅内感染后使用利奈唑胺治疗的患者病历资料，根据利奈唑胺治疗前后患者症状、体温、脑脊液细菌培养结果及脑脊液白细胞数、蛋白质、葡萄糖变化等指标，参照颅内感染的判定标准，评价患者使用利奈唑胺治疗颅内感染的有效性及安全性。结果51例神经外科术后发生颅内感染的患者在使用利奈唑胺治疗后，感染痊愈30例，显效12例，进步5例，无效4例，总有效率92.16%。有效的47例患者中，利奈唑胺的平均治疗时间为12.5 d(2~27 d)。其中11例脑脊液培养出革兰阳性菌者经利奈唑胺治疗后，脑脊液细菌培养均转为阴性。结论利奈唑胺可有效控制万古霉素等治疗无效的葡萄球菌属、肠球菌属等革兰阳性菌引起的术后颅内感染。
목적：평개리내서알치료신경외과술후로내감염적림상료효급안전성，위술후로내감염적치료제공삼고。방법통과병력사순계통수집2011년1월-2012년12월북경천단의원51례술후로내감염후사용리내서알치료적환자병력자료，근거리내서알치료전후환자증상、체온、뇌척액세균배양결과급뇌척액백세포수、단백질、포도당변화등지표，삼조로내감염적판정표준，평개환자사용리내서알치료로내감염적유효성급안전성。결과51례신경외과술후발생로내감염적환자재사용리내서알치료후，감염전유30례，현효12례，진보5례，무효4례，총유효솔92.16%。유효적47례환자중，리내서알적평균치료시간위12.5 d(2~27 d)。기중11례뇌척액배양출혁란양성균자경리내서알치료후，뇌척액세균배양균전위음성。결론리내서알가유효공제만고매소등치료무효적포도구균속、장구균속등혁란양성균인기적술후로내감염。
Objective To assess clinical efficacy and safety of linezolid in treating postoperative intracranial infec-tion after neurosurgery operation,and provide clinical basis for the treatment of postoperative intracranial infection. Methods From January 2011 to December 2012,clinical data of 51 neurosurgery patients receiving linezolid for trea-ting postoperative intracranial infection were collected,changes in symptoms,temperature,cerebrospinal fluid (CSF)bacterial culture,as well as white blood cell (WBC)count,protein and glucose in CSF before and after therapy were compared,clinical efficacy and safety of linezolid in the treatment of postoperative intracranial infection were assessed based on the diagnostic criteria for intracranial infection.Results After linezolid treatment,30 cases of postoperative intracranial infection were cured,and linezolid was effective in 1 2 cases,improved in 5 cases,and ineffective in 4 cases,total effective rate was 92.16%.Of 47 cases with effective therapy,the mean therapy day were 12.5 d (2-27 d),11 of whom isolated gram-positive bacteria from CSF before therapy,and CSF culture were all negative after linezolid therapy.Conclusion Linezolid is effective for treating intracranial infection caused by Staphylococci,Enterococci and other gram-positive bacteria which failed to response to vancomycin therapy.